March 6, 2026 argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
February 26, 2026 argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
February 26, 2026 argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Follow us
Get the latest news and info via our social media channels.